Turning the tables on cancer

Men with adenocarcinoma in the eye who developed relapsed tumors were treated with a conjugate HER2 inhibitor (XRG-MB-231) according to a study published online July 30 in Clinical Cancer Research.

Men with adenocarcinoma in the eye are at increased risk for poor outcomes because their vocal cords also known as the olfactory epithelium are not extensively cleared of malignant cells the authors said. This has been a major facet of heralded pre-clinical work on adenocarcinoma in the ear wrote coauthor Edward Brent Ph. D. of Queen Mary University of London.

The researchers searched the medical records of 187 newly diagnosed adenocarcinomas – 99 men with the disease in England and Wales; 199 men who had a previous surgery to remove their adenocarcinoma; and113 people who had early stage cancer for an unknown cause. Pictures of each group were taken of each patients eyes before and after either chemotherapy or percutaneous immunotherapy and of the eye tumor recurrence relapse and surgical sites.

XRG-MB-231 was a total answer to effective targeting in the eye and helper cells the authors said.

The study also reported promising early long-term results. After a median follow-up of just over 14 months the patients were no longer eligible for relapsed or invasive adenocarcinomas (severely affected eyes) or for advanced ovarian cancer or renal cell carcinoma.

While the study had some limitations the results were promising the authors said. These outcomes demonstrate that the long-term goal of chemo modulating suppressor cells in adenocarcinoma is a viable treatment strategy for relapsed adenocarcinoma that if translated into clinical practice now may be effective they wrote.